Cat. No.: HY-N0257

Epimedin A

4 Cited Publications

Customer Review

Based on 4 publication(s) in Google Scholar

Epimedin A, one of the main flavonoid active components in Herba Epimedii, is orally active. Epimedin A can inhibit osteoclastogenesis, differentiation, and bone resorption. Epimedin A also possesses anti-inflammatory activity. Epimedin A can be used in the research of osteoporosis and inflammatory diseases.

For research use only. We do not sell to patients.

Purity: 99.43%
CAS No.: 110623-72-8
Formula: C₃₉H₅₀O₂₀
Molecular Weight:838.80

Storage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Epimedin A Chemical Structure

CAS No.: 110623-72-8

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (4)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target^[2]

NLRP3

HO-1

Caspase-1

Caspase-8

IL-1β

IL-6

All PI3K Isoforms :

All Akt Isoforms :

All NF-κB Isoforms :

All NOD-like Receptor (NLR) Isoforms :

All Heme Oxygenase (HO) Isoforms :

HO-1
HO-2

All Caspase Isoforms :

All Interleukin Related Isoforms :

In Vitro

Epimedin A (0.1-0.4 μM; 5 days) inhibits RANKL/M-CSF-induced osteoclast differentiation and reduces the mRNA expression of osteoclast-related genes in RAW264.7 cells. The mechanism involves the inhibition of the TRAF6/PI3K/AKT/NF-κB pathway^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Real Time qPCR^[1]

Cell Line:

RAW264.7 cells treated RANKL and M-CSF
Concentration:

0.1, 0.2 and 0.4 μM
Incubation Time:

5 days
Result:

Inhibited the mRNA levels of the osteoclast-related genes NFATc1, Ctsk, Oscar and Trap.

In Vivo

Epimedin A (5-20 mg/kg; oral administration; 90 days) has a therapeutic effect in a rat model of osteoporosis^[1].
Epimedin A (5-20 mg/kg; oral administration; 11 days) exerts an anti-inflammatory effect in a mouse model of allergic contact dermatitis (CD)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female Wistar rats (240±20 g, 10-12 weeks old) were ovariectomized to establish an osteoporosis model^[1]
Dosage:

5, 10 and 20 mg/kg
Administration:

Oral administration; 90 days
Result:

Increased bone density, relative bone volume, trabecular thickness and number, as well as reduced trabecular separation in the ovariectomized rats.
Dose-dependently normalized bone density and trabecular microarchitecture in the ovariectomized rats.
Inhibited the expression of TRAP and NFATc1 in the ovariectomized rats.

Animal Model:

BALB/c mice aged 7 weeks old (20-25 g) treated DNFB to establish CD model^[2]
Dosage:

5, 10 and 20 mg/kg
Administration:

Oral administration; 11 days
Result:

Significantly and dose-dependently ameliorated DNFB-induced CD, as evidenced by repression of scratching behavior, dermatitis score, ear thickness and weight, and histopathological changes in ear tissues, as well as reduction of collagen fiber area percent.
Suppressed NF-κB/NLRP3 pathway, enhanced Nrf2/HO-1 pathway, reduced oxidative stress markers (MDA), increased antioxidant markers (GSH, SOD), inhibited pyroptosis-related molecules (NLRP3, ASC, caspase-1, 8, GSDMD, LDH), and decreased inflammatory cytokines (IL-1β, IL-6, TNF-α, IL-4, IFN-γ) and IgE levels (t-IgE, s-IgE, s-IgE/t-IgE ratio).

Chemical Information

CAS No. 110623-72-8
Appearance Solid
Molecular Weight 838.80
Formula C₃₉H₅₀O₂₀
Color Light yellow to yellow
SMILES

O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](OC2=CC(O)=C(C(C(O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O[C@@]4([H])[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)=C(C5=CC=C(OC)C=C5)O6)=O)C6=C2C/C=C(C)/C)[C@@H]1O
Structure Classification
- Flavonoids
- Flavonols
- Phenols
- Monophenols
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (4)

All

Sort by:

Journal Impact Factor

Acta Pharm Sin B

Chrysin serves as a novel inhibitor of DGK α/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC). [Abstract]

2021 Jan;11(1):143-155. PMID: 33532186
Food Chem

Effects of sun drying combined with baking processes on the flavor quality of Chongqing Tuocha raw tea. [Abstract]

2025 Dec 30:497:146992. PMID: 41285060
Food Chem

Flavonoid-mediated metabolic underpinning quality variation in red bud-sport pear mutants. [Abstract]

2025 May 31:489:144992. PMID: 40466530
J Pharm Pharmacol

Icariside I reduces breast cancer proliferation, apoptosis, invasion, and metastasis probably through inhibiting IL-6/STAT3 signaling pathway. [Abstract]

2024 May 3;76(5):499-513. PMID: 37971302

Solvent & Solubility

In Vitro:

DMSO : 250 mg/mL (298.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.1922 mL

5.9609 mL

11.9218 mL

5 mM

0.2384 mL

1.1922 mL

2.3844 mL

10 mM

0.1192 mL

0.5961 mL

1.1922 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass

Concentration

Volume

Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 6.25 mg/mL (7.45 mM); Clear solution

This protocol yields a clear solution of ≥ 6.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (62.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 6.25 mg/mL (7.45 mM); Clear solution

This protocol yields a clear solution of ≥ 6.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (62.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage
mg/kg
Animal Weight (Per Animal)
g
Dosing Volume (Per Animal)
μL
Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (285 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Li J, et al. Epimedin A inhibits the PI3K/AKT/NF-κB signalling axis and osteoclast differentiation by negatively regulating TRAF6 expression. Mol Med. 2024 Aug 16;30(1):125. [Content Brief]

[2]. Balaha MF, et al. Epimedin A ameliorates DNFB-induced allergic contact dermatitis in mice: Role of NF-κB/NLRP3-driven pyroptosis, Nrf2/HO-1 pathway, and inflammation modulation. Life Sci. 2022 Aug 1;302:120653. [Content Brief]

[3]. Zhang HF, et al. Simultaneous extraction of epimedin A, B, C and icariin from Herba Epimedii by ultrasonic technique. Ultrason Sonochem. 2008 Apr;15(4):376-85. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.1922 mL	5.9609 mL	11.9218 mL	29.8045 mL
	5 mM	0.2384 mL	1.1922 mL	2.3844 mL	5.9609 mL
	10 mM	0.1192 mL	0.5961 mL	1.1922 mL	2.9804 mL
	15 mM	0.0795 mL	0.3974 mL	0.7948 mL	1.9870 mL
	20 mM	0.0596 mL	0.2980 mL	0.5961 mL	1.4902 mL
	25 mM	0.0477 mL	0.2384 mL	0.4769 mL	1.1922 mL
	30 mM	0.0397 mL	0.1987 mL	0.3974 mL	0.9935 mL
	40 mM	0.0298 mL	0.1490 mL	0.2980 mL	0.7451 mL
	50 mM	0.0238 mL	0.1192 mL	0.2384 mL	0.5961 mL
	60 mM	0.0199 mL	0.0993 mL	0.1987 mL	0.4967 mL
	80 mM	0.0149 mL	0.0745 mL	0.1490 mL	0.3726 mL
	100 mM	0.0119 mL	0.0596 mL	0.1192 mL	0.2980 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Epimedin A

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Glycoside Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Medicine Food Homology Compound Library

Phenols Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Flavonoids Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Protease Inhibitor Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cytokine Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Pattern Recognition Receptors Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Epimedin A

All PI3K Isoforms

All Akt Isoforms

All NF-κB Isoforms